So far, DYRK1A has been the main target for therapeutic research, leading to the identification of compounds that inhibit its protein kinase activity and are able to improve cognition in mouse models for DS (Guedj et al., 2009; De la Torre et al., 2014, 2016; Kim H. et al., 2016; Nakano-Kobayashi et al., 2017; Neumann et al., 2018; Nguyen et al., 2018). The gene discussed is DYRK1A; the disease is Dravet syndrome.